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Abst ract
Extraskeletal myxoid chondrosarcomas (EMC) are extre mely
rare and are usually located in the deep soft tissues of the low-
er extremities. Less than 10 cases of intracranial EMC have
been reported in the literature, making their management and
early diagnosis difficult. We present a new case of intracranial
EMC occurring in a 70-year-old woman presenting with
a right frontal mass initially assumed to be a brain metastasis
from breast adenocarcinoma. The optimal management of these
tumours is also discussed. Analysis from the literature suggests
that complete resection should be recommended, whenever fea-
sible. Although the high risk for relapse after surgery encou -
rages postoperative treatments, relative resistance to both ra-
dio therapy and chemotherapy characterizes EMC. Future
perspectives might include multimodal treatments with high-
ly conformal radiotherapy modalities for dose escalation stra-
tegies or use of new molecules. Knowledge of these unusual
malignant tumours will be the first step for improving patients’
outcome.
Key words: intracranial tumour, extraskeletal myxoid chon-
drosarcoma, brain neoplasm.
Primary intracranial extraskeletal myxoid chondrosarcoma
Pierwotny œródczaszkowy pozaszkieletowy chrzêstniakomiêsak œluzowaty
Renaud Dulou1, Cyrus Chargari2, Arnaud Dagain1, Christophe Teriitehau3, Olivier Goasguen1, Olivier Jeanjean4, Lionel Védrine2
1Department of Neurosurgery, Val-de-Grâce Hospital, Paris, France
2Department of Oncology and Radiotherapy, Val-de-Grâce Hospital, Paris, France
3Department of Radiology, Percy Hospital, Clamart, France
4Palliative Care Centre, La Martiniere Institute, Saclay, France
Neurologia i Neurochirurgia Polska 2012; 46, 1: 76-81
DOI: 10.5114/ninp.2012.27176
CASE REPORT/OPIS PRZYPADKU
St reszc zenie
Pozaszkieletowy chrzêstniakomiêsak œluzowaty to wyj¹tkowo
rzadki guz, który wystêpuje zwykle g³êboko w tkankach miêkkich
koñczyn dolnych. Opisano mniej ni¿ 10 przypadków tego guza
umiejscowionych œródczaszkowo, co utru dnia wczes ne rozpo-
znanie i leczenie. W pracy przedstawiono nowy przypadek œród-
czaszkowego chrzêstniakomiêsaka œluzowatego u 70-letniej 
kobiety z guzem okolicy czo³owej prawej, traktowanym
pocz¹tkowo jako przerzut gruczolakoraka sutka do mózgu.
Omówiono optymalne leczenie tych guzów. Analiza piœmien-
nictwa wskazuje, ¿e w miarê mo¿liwoœci powinno siê zalecaæ
ca³kowite wyciêcie. Du¿e ryzyko wznowy po leczeniu chirur-
gicznym sk³ania do podejmowania dodatkowego leczenia, 
ale guz charakteryzuje siê wzglêdn¹ opornoœci¹ na radiotera-
piê i chemioterapiê. Przysz³e wielorakie metody leczenia
mog³yby wykorzystywaæ radioterapiê konformaln¹ w celu
zwiêkszenia dawki promieniowania lub zastosowanie nowych
cz¹steczek. Wiedza o tych rzadkich nowotworach z³oœliwych
bêdzie pierwszym krokiem do poprawy wyników leczenia.
S³owa kluczowe: guz œródczaszkowy, pozaszkieletowy chrzêst-
niakomiêsak œluzowaty, nowotwór mózgu.
Introduction
Cartilaginous tumours represent less than 0.15% of
intracranial neoplasms [1]. Intracranial chondrosarco-
mas are supposed to originate from embryonic rests of
the chondrocranium or from metaplasia of meningeal 
fibroblasts and typically arise from the base of the skull
[2]. There is growing biological evidence that skeletal
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chon drosarcoma should be distinguished from extra ske-
letal myxoid chondrosarcoma (EMC), which is an excep -
tional entity that accounts for less than 2% of soft tissue
sarcoma. While about 75% of cases of myxoid sarcomas
are located in the deep soft tissues of the lower extremi -
ties, less than ten cases of intracranial EMC have been
reported in the literature [2]. Although the management
of patients with intracranial EMC remains uncertain, 
better knowledge of these unusual locations could help
neurosurgeons and other physicians to deliver an appro -
priate treatment.
Here, we present a new case of intracranial EMC 
occurring in a 70-year-old woman presenting with
a right frontal mass initially assumed to be a brain metas-
tasis of a breast adenocarcinoma. The optimal manage-
ment of these tumours is also discussed through a review
of the literature.
Case report
A 70-year-old, right-handed woman presented with
a two-month history of behavioural changes and pro-
gressive difficulty with walking. Two years before, she had
presented a trifocal adenocarcinoma of the breast with
three axillary node metastases (pT1c pN1 M0, stage IIA),
characterized by no expression of oestrogen or proges-
terone receptors and no amplification of human epider-
mal growth factor receptor 2 (HER2/neu). She had been
treated with mastectomy with axillary lymph node dis-
section and had received adjuvant radiotherapy and
chemotherapy.
On the day of admission, neurological examination
revealed right hemiparesis sparing the face and global
aphasia. The magnetic resonance imaging (MRI) show -
ed a heterogeneously enhancing rounded mass in the left
frontal lobe (Fig. 1), which suggested a primary intra -
cranial lesion. A computed tomography (CT) scan of the
chest and abdomen failed to show any other suspicious
lesion but indicated a subclinical pulmonary embolism
which was a contraindication for intracranial surgery for
two months.
After multidisciplinary discussion, it was decided to
irradiate the lesion during this period. The patient received
a total dose of 60 Gy, in 30 daily fractions. The post-
irradiation MRI showed a slight increase in tumour 
volume. Then, the patient was operated on with neuro -
navigation. The tumour was totally removed piecemeal.
Its dissection was non-haemorrhagic and did not show
any signs of former radiotherapy. It was pearly white, with
a lobular appearance, firm to slightly hard in consisten-
cy. It appeared strictly extra-axial, but was less clearly 
demarcated at its deep margins during dissection from
the cerebral cortex. The perioperative impression was 
consistent with a meningioma although the lesion had no
dural attachment. The postoperative course was event-
less, with total recovery of the hemiparesis but persistence
of aphasia and mental disturbances.
Microscopic examination of the lesion showed a pro-
liferation of cells in a multilobular arrangement within
an abundant myxoid stroma (Fig. 2). Neither haemor-
rhage nor necrosis was observed. No mitosis was seen.
In the periphery, the lesion was more cellular and infil-
Fig. 1. A) Axial T2-weighted magnetic resonance (MR) image showing hyperintense mass in the left frontal lobe with surrounding oedema; B) axial and C) coronal 
T1-weighted MR images revealing ring enhancement of the lesion
A B C
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trated into brain parenchyma. Immunohistochemical stud-
ies showed that the cells were strongly positive for pan-
cytokeratin AE1 and AE3, EMA, and less positive for
anti PS-100. Numerous nuclei of tumour cells were pos-
itive for MIB1 staining. The histological diagnosis was
myxoid chondrosarcoma.
Unfortunately, the patient presented three months 
later with a worsening of mental troubles with severe at-
tention deficit hyperactivity disorder and apathy. An MRI
scan showed recurrence of the tumour in the same site.
Intravenous chemotherapy with ifosfamide was given
(1000 mg/m2 daily for five days every three weeks). 
After four cycles of this regimen, no clinical benefit was
noted and MRI showed moderate progression of the 
intracranial lesion. Chemotherapy was withdrawn and 
the patient received the best supportive care. She died ten
months after surgery in a palliative care centre.
Discussion
Primary extraskeletal chondrosarcomas are inter-
mediate-grade malignant neoplasms, which are charac-
terized by a high propensity to local recurrence and
metastatic evolution [2]. At the time of diagnosis, average
age is around 50 years, with a male-to-female ratio of 
2 : 1. Since these tumours frequently have an indolent
clinical presentation, extraskeletal chondrosarcomas are
frequently diagnosed at a late stage, when complete re-
section has become technically difficult. These tumours
are usually classified into two histological subtypes: me -
senchymal and myxoid type [3]. The myxoid variant has
particular morphological and cytogenetic features and it
is the rarest one [4]. Ultrastructural and molecular stud-
ies suggested that skeletal myxoid chondrosarcomas 
and EMC are two separate entities rather than the same
entity arising in two different locations: detection of
a EWS-CHN gene fusion RNA resulting from the t
(9;22) mutation would be highly specific to EMC [5,6].
EMC is thought to be a tumour of intermediate malig-
nancy, but with a supposed better prognosis than other
types of chondrosarcomas [7,8]. Tumour size, cellular
density, presence of anaplasia or rhabdoid features,
high mitotic activity, and high Ki67 have been reported
Fig. 2. Light micrograph of the tumour showing lobules and cords of tumour
cells embedded within a myxoid stroma (haematoxylin and eosin stain, × 10)
First author Recurrence Cellularity Necrosis Mitotic activity Tumour size
(year of publication)
Scott (1976) [14] Deceased Variable No NR NR
Smith (1981) [15] No Variable NR Low 3.5 × 1 × 0.5 cm
Cybulski (1985) [11] No NR NR No NR
Salcman (1992) [8] Yes 1: moderate NR High 1: 7 × 5 × 4 cm
2: higher* 2: NR*
Sato (1993) [13] No NR No Low NR
Chaskis (2002) [10] Deceased NR NR Low NR
González-Lois (2002) Yes 1-2: low NR 1-2: low NR
[12] 3: higher* 3: higher*
Im (2003) [7] No Variable No Low 1.2 × 1 × 1 cm
Cummings (2004) [6] NR Variable NR Low 2.4 × 1.8 × 2.3 cm
Current case Yes Low No No 4 × 4 × 3.5 cm
Table 1. Histopathological characteristics of the intracranial extraskeletal myxoid chondrosarcoma cases
*1, 2, 3 – number of tumour recurrence
NR – not reported
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to be adverse pathological prognostic factors, but the rar-
ity of intracranial locations does not allow for validation
of those factors as significant prognostic factors for sur-
vival (Table 1) [9].
In order to highlight optimal strategies for manage-
ment of intracranial EMC, we conducted a search in 
the literature using the Medline database (PubMed,
http://ncbi.nlm.nih.gov/PubMed) for the keywords 
‘extraskeletal myxoid chondrosarcoma’, ‘brain neo-
plasm’, and ‘intracranial tumour’, between 1970 and 2010.
The manuscripts were reviewed and their bib liographies
scanned for additional articles. Nine previously report-
ed cases of intracranial extraskeletal myxoid chon-
drosarcoma were found [6-8, 10-15]. Their features are
reported in Table 2. Age at the time of diagnosis ranged
from 12 to 69 years. The duration of symptoms depended
on the location of the tumour (four days for the patient
with cerebellar EMC, more than three years for the pa-
tient with right frontoparietal location).
No definitive conclusion could be drawn from the 
lite rature regarding the exact site of tumour origin in 
intracranial extraskeletal cases. In the unique case of chon-
drosarcoma of the fourth ventricle, the tumour was
thought to arise from the stroma of the choroid plexus
[14]. For the cases in which the tumour is attached to
or infiltrates the falx, tentorial or dural sinuses, it is usu-
ally assumed that the tumour could derive from meningeal
fibroblasts. In our case, however, neither dural attachment
nor dural invasion by the tumour was found. The tumour
was characterized by the absence of a true cleavage plane
First  Age Duration of Location/ Surgery Postope- Time to Treatment Survival Follow-up
author (years), symptoms origin extent rative recurrence of recurrence duration
(year of gender before within treatment
publication) treatment brain
Scott 39, M 5 months Fourth Partial No NA NA 13 days 13 days
(1976) [14] ventricle
Smith 12, M 4 days Posterior Complete No NA NA NR 13 months
(1981) [15] cranial 
fossa
Cybulski 58, M 1 week Falx Complete No NA NA NR 18 months
(1985) [11]
Salcman 28, F 2 months Left Complete No 10 months Total NR 22 months
(1992) [8] parafalcine removal 
area and BT
Sato 43, F 2 months Pineal Partial RT and NA NA 37 months 37 months
(1993) [13] region chemothe-
rapy
Chaskis 69, M 3 months Right Complete No NA NA 1 month  
(2002) [10] frontal (septic
lobe shock)
González- 17, F > 3 years Right, Complete No 16 months Total NR 20 months
Lois fronto- removal 
(2002) [12] parietal and RT
Im 43, M 2 months Left Complete RT NA NA 36 months 36 months
(2003) [7] parietal 
lobe
Cummings 63, M 1 year Right Complete NR NR NR NR NR
(2004) [6] cerebello-
pontine 
angle
Current 70, F 2 months Left Complete RT 3 months Chemotherapy 5 months 5 months
case frontal before
lobe surgery
Table 2. Review of intracranial extraskeletal myxoid chondrosarcoma cases reported in the literature
BT – brachytherapy, F – female, M – male, NA – not applicable, NR – not reported, RT – radiotherapy 
Intracranial extraskeletal myxoid chondrosarcoma
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First author T1-weighted Contrast enhancement T2-weighted Oedema
(year of publication)
Salcman (1992) [8] Hypointense NR Homogeneous hyperintense No
Chaskis (2002) [10] NR Strong and homogeneous NR Yes
González-Lois (2002) [12] Hypointense Strong and heterogeneous NR NR
Im (2003) [7] Hypointense Strong and homogeneous Slightly hyperintense Yes
Cummings (2004) [6] NR Strong and heterogeneous NR NR
Current case Hypointense Strong and heterogeneous Homogeneous hyperintense Yes
Table 3. The magnetic resonance imaging characteristics of intracranial extraskeletal myxoid chondrosarcomas cases reported in the literature
NR – not reported
deep within the operating field and the presence of his-
tological signs of parenchymal infiltration. The site of ori-
gin in this case could be the leptomeningeal sheath around
vessels or the vessel walls in the depth of a sulcus, as was
hypothesized for other patients with intraparenchymal 
locations reported in the literature.
Regarding radiological features, intracranial EMC
usually present as hypointense well-demarcated lesions
with strong enhancement after contrast injection on 
T1-weight ed sequences and high intensity on T2-weight-
ed sequences (Table 3). In the case of our patient with
a previous history of breast carcinoma, the heterogeneously
enhancing lesion could mimic a metastatic brain tumour,
which should be considered as a differential diagnosis.
Histological confirmation of the diagnosis should be 
a priority whenever feasible, since radiological features
are not specific.
The optimal treatment of intracranial EMC remains
uncertain. In the previous cases of intracranial EMC,
complete removal was achieved for all but two patients.
Two patients died during the month following surgery.
One patient with complete removal and another patient
with partial surgery received postoperative external
beam radiotherapy then chemotherapy was delivered for
the latter. For six patients, follow-up was reported (du-
ration: 13-37 months). Three of them experienced tu-
mour relapse, treated either with salvage surgery (n = 1),
radiotherapy (n =1), or brachytherapy (n = 1). Five pa-
tients were alive at the last follow-up. Altogether, these
observations suggest that surgery should be the first-line
treatment. It also allows the determination of the final 
diagnosis. However, total removal of the tumour does not
seem to be sufficient to prevent short-term recurrence as
in the case of our patient. Probably, useful information
could be obtained through analysis of literature on EMC
from other sites. In their experience, Kawaguchi et al. 
reported on 20 males and 22 females with histological-
ly confirmed EMC. Mean age at diagnosis was 52.1 years.
Univariate analysis revealed that inadequate initial
surgery was a significant prognostic factor for local re-
currence. After wide excision, only 14% patients had re-
lapsed, supporting the role of complete excision in the 
local control of the disease [16]. Unfortunately, such func-
tionally safe wide excision is usually not possible for pa-
tients with intracranial EMC, and their prognosis remains
particularly poor [10].
Combined with the very low number of patients, the
relative resistance to ionizing radiation of chondrosarcoma
could explain the lack of marked benefit demonstrated
for adjuvant radiotherapy in patients with EMC. How-
ever, this treatment is usually proposed after surgery if
recurrence occurs or when the lesion is inoperable or only
partially removed. Since most patients with intracranial
EMC cannot be offered microscopically complete resec -
tion, delivering irradiation could be logically proposed
as adjuvant therapy. However, the risk of relapse is im-
portant when surgery is marginal, and this risk will not
be counterbalanced by postoperative radiotherapy [12].
Although not demonstrated, new highly conformal ir-
radiation modalities such as helical tomotherapy and gam-
ma knife could be potentially used for treatment of tu-
mour relapse or management of inoperable patients. 
By sparing critical organs from irradiation, dose escala-
tion strategies could potentially overcome this intrinsic
resistance to ionizing radiation.
Few data have been reported regarding the place of
chemotherapy for management of unresectable disease.
Therapeutic agents used for other locations of EMC are
the same as those used for soft-tissue sarcomas and 
include doxorubicin, dacarbazine, beta-interferon, and
ifosfamide, but these drugs lack significant evidence of
efficacy in this setting [17,18]. Drilon et al. reported a ret-
rospective review on 87 patients with EMC from two 
referral centres. The authors found that 37% of patients
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presenting with a local disease developed distant metas-
tases within a median time of 3.3 years. The 5-year, 
10-year, and 15-year overall survival rates were 82%, 65%,
and 58%, respectively. However, the progression-free sur-
vival at 9 months was only 26%, with no significant re-
sponses noted in 21 patients receiving chemotherapy. This
analysis highlighted that aggressive control of localized
disease should be the first-line treatment [2]. Although
no data have been reported on the place of chemothe rapy
for the management of patients with intracranial EMC,
its efficacy will probably be limited by intrinsic drug re-
sistance of the tumour and by the additional theoretical
obstacle of the blood-brain barrier. New molecules and
targeted agents are being developed for the treatment 
of soft tissue sarcoma. By targeting specific molecular 
alte ration, those could significantly improve the outcome
of patients.
In conclusion, EMC is a neoplasm only rarely en-
countered intracranially, and thus defining an optimal the -
rapeutic strategy is difficult. Altogether, our clinical 
presentation and analysis from the literature suggest that
these rare locations are associated with a poor progno-
sis despite total removal of the tumour. Moreover, it is
difficult to extrapolate the treatment outcome of patients
with EMC located elsewhere, since surgical conditions
are substantially different here. Further improvements in
the management of patients with EMC could be achiev -
ed with the area of targeted agents and new irradiation
modalities. In all cases, multidisciplinary management
should be strongly recommended for those rare tumours.
Better knowledge of these unusual tumours will reduce
diagnostic delays and hopefully improve patients’ out-
come.
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